Salute e Benessere

OSE Immunotherapeutics provides an update on ongoing proceedings

OSE Immunotherapeutics provides an update on ongoing proceedingsNantes, June 25 th, 2025, 8:00 a.m.-OSE Immunotherapeutics SA( ISIN: FR0012127173; Mnemo: OSE),announces that, following the hearing on June 24th, 2025, regarding the request to retract the June 10 th, 2025 order by the President of the Nantes Commercial Court, who authorized the postponement of the annual shareholders’ meeting of OSE, the deliberation is expected to occur on Tuesday, July 1 st, 2025.OSE...
Nasdaq GlobeNewswire
25/06/2025

LIfT BioSciences Expands U.S. Footprint with New Facility at Portal Innovations…

LIfT BioSciences Expands U.S. Footprint with New Facility at Portal Innovations, Houston Helix Park London,25 June 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces it has entered into an agreement with Portal Innovations, a life sciences venture capital firm, providing LIfT with access to Portal’s state-of-the-art 30,000 sq. ft. labs and office space in Houston Helix Park, Texas, one of the...
Nasdaq GlobeNewswire
25/06/2025

Novo Nordisk Foundation and University of Copenhagen announce USD 109 million…

But imagine if proteins could be specifically designed to provide even more versatile molecular toolboxes for science, technology and healthcare. In essence, this is what protein design is all about. It is a growing field that allows scientists to create entirely new proteins – including those that nature itself has not explored – and to tailor them to solve specific challenges. But imagine if proteins could be specifically designed to provide even more versatile molecular toolboxes for...
PR Newswire
25/06/2025

Idorsia launches repurchase offer for its 2025 and 2028 convertible bonds

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – June 25, 2025Idorsia Ltd (SIX: IDIA) today announced the launch of the repurchase offer to the holders of its outstanding CHF 200 million convertible bonds maturing in 2025 ( CB 2025 ; ISIN CH0426820350), and CHF 600 million convertible bonds maturing in 2028 ( CB 2028 ; ISIN CH1128004079) (theRepurchase Offer ).The Repurchase Offer is part of a larger holistic restructuring, as announced in apress releaseon...
Nasdaq GlobeNewswire
25/06/2025

Addex Shareholders Approve All Resolutions at Annual General Meeting

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2025-Addex Therapeutics(SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all proposals of the board of directors in its 2025 Annual General Meeting (AGM). The votes represented 30.18% of the company's outstanding capital.Addex shareholders approved...
Nasdaq GlobeNewswire
25/06/2025

Novartis announces expiration of Regulus Therapeutics tender offer

Basel, June 25, 2025– Novartis today announced that its previously announced tender offer (the “Offer”) by Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), to acquire all of the outstanding shares of common stock, par value $0.001 per share (the “Shares”), of Regulus Therapeutics Inc. (“Regulus”), in exchange for (i) $7.00 in cash per share, subject to any applicable withholding and without interest thereon, plus (ii) one...
Nasdaq GlobeNewswire
25/06/2025

Press Release: Riliprubart earns orphan drug designation in the US for…

Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantationOngoing phase 2 study evaluating riliprubart for the potential prevention and treatment of active antibody-mediated rejection in kidney transplant recipientsRiliprubart was also designated orphan drug for the investigational use in chronic inflammatory demyelinating polyneuropathy in the US and EUParis, June 25, 2025. The US Food and Drug Administration (FDA) has...
Nasdaq GlobeNewswire
25/06/2025

Leica Biosystems Unveils Next-Gen Pathology Portfolio at ECDP 2025

At the heart of this innovation is a comprehensive range of high-performance scanners and intelligent software, enabling all users from academic researchers to clinical diagnosticians to Scan, Manage, and Analyze their slides. We welcome you to join us and see our new solutions in action. At the heart of this innovation is a comprehensive range ofhigh-performance scannersandintelligent software, enabling all users from academic researchers to clinical diagnosticians to Scan, Manage, and...
PR Newswire
25/06/2025

TVM Capital Healthcare Appoints Dr. Su-Lin Chong in Malaysia as Investment…

She began her career in hospital management at Subang Jaya Medical Centre, now part of Asia OneHealthcare, and later became founding CEO and Project Director for International Medical University's planned medical centre. Dr. Chong also served as CEO of Sunway Medical Centre for 11 years, as well as held other key hospital management leadership positions, including CEO of Beacon International Specialist Centre and Prince Court Medical Centre. She began her career in hospital management at…
PR Newswire
25/06/2025

BAFF- and APRIL-targeted Therapies Market Sees Surge in Activity Amid Rising…

Key Takeaways from the BAFF- and APRIL-targeted Therapies Market Report Key Takeaways from the BAFF- and APRIL-targeted Therapies Market Report Discover which indication is expected to grab the major BAFF- and APRIL-targeted therapies market share @ BAFF- and APRIL-targeted Therapies Market Report BAFF- and APRIL-targeted Therapies Market Dynamics The BAFF- and APRIL-targeted therapies market is evolving rapidly, driven by agrowing understanding of B-cell biologyand its...
PR Newswire
24/06/2025

Final results of Bioretec Ltd's successful rights issue

The final results of Bioretec Ltd's ("Bioretec" or the "Company") rights issue (the "Offering") show that a total of 7,658,836 new shares (the "New Shares") were subscribed for in the Offering, corresponding to approximately 124.4 per cent of the 6,156,618 New Shares offered in the Offering, and the Offering was thus oversubscribed. A total of 4,882,744 New Shares were subscribed for with subscription rights, corresponding to approximately 79.3 per cent of…
PR Newswire
24/06/2025

Arcoma AB successfully completes directed share issue of SEK 11.0 million (~ EUR…

Arcoma AB successfully completes directed share issue of SEK 11.0 million (~ EUR 1 million)NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE CONTRAVENING TO ANY APPLICABLE RULES OR REQUIRE REGISTRATION OR OTHER ACTIONS...
Nasdaq GlobeNewswire
24/06/2025

CROSSJECT announces a successful capital increase of €5.7 million following full…

Press releaseCROSSJECT announces a successful capital increase of €5.7 million following full exercise of the extension clauseTransaction raised to over 5.7 million euros following full exercise of the extension clause. Total demand of over 9,2 million euros, representing an oversubscription rate of 1.84x.Transaction benefited from the support of Gemmes Venture and investment by new investor Vatel Capital.Dijon, France June 24, 2025 (7.00 PM CET) -- CROSSJECT (ISIN:...
Nasdaq GlobeNewswire
24/06/2025

Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the…
PR Newswire
24/06/2025

Ovarian Cancer Drugs Market Size expected to reach US$ 4.23 billion by 2031 |…

Common chemotherapy drugs for ovarian cancer are platinum-based medications such as carboplatin and cisplatin, as well as taxanes such as paclitaxel. Other drugs, such as bevacizumab and topotecan, may also be utilized. Targeted therapies, including PARP inhibitors such as olaparib, rucaparib, and niraparib, are particularly effective for specific types of ovarian cancer, especially those associated with BRCA gene mutations. Additionally, mirvetuximab soravtansine is a monoclonal antibody that…
PR Newswire
24/06/2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2025

Aggregated presentation by day and by market Statement of transactions in own shares from June 16th to June 20th 2025 Name of the issuerIdentity code of the issuer(Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket(MIC Code) IPSEN549300M6SGDPB4Z94P1116/06/2025FR0010259150 140 103,60...
Nasdaq GlobeNewswire
24/06/2025

LiberNovo Omni Is Live: Support Smarter Sitting

We sit too much — an average of 9.5 hours a day — our bodies aren't built for that, and your "ergonomic computer chair" definitely isn't. We sit too much — an average of 9.5 hours a day — our bodies aren't built for that, and your "ergonomic computer chair" definitely isn't. Omni is. It solves the problem every other chair ignores: how to deliver comfort, movement, and support without compromise. This isn't static sitting, it's dynamic ergonomics designed to fit your body…
PR Newswire
24/06/2025

Major shareholder notification – BlackRock, Inc.

GN Store Nord A/S hereby announces that on June 23, 2025, pursuant to Section 38(1) and Section 39(1) of the Danish Capital Markets Act, it received a notification from BlackRock, Inc. stating that on June 20, 2025, BlackRock, Inc. reduced its aggregate direct and indirect holding of shares and financial instruments, cf. Section 38 and Sections 39(2)(1) and (2) of the Danish Capital Markets Act, to below 5% of the share capital and voting rights in GN Store Nord A/S. For further information,...
Nasdaq GlobeNewswire
24/06/2025

Electrotherapy Systems Market Size to Surpass USD 9.42 Billion by 2031…

Market growth: The electrotherapy systems market value is expected to reach USD 9.42 billion by 2031 from USD 4.99 billion in 2024; it is anticipated to record a CAGR of 8.1% during the forecast period. Electrotherapy systems serve as non-drug, noninvasive methods for pain relief and rehabilitation, which makes them highly popular in hospitals, clinics, and home care settings. Market growth: The electrotherapy systems market value is expected to reach USD 9.42 billionby 2031fromUSD 4...
PR Newswire
24/06/2025

Pet Oral Care Market to Reach USD 3 Billion by 2032 at a CAGR of 6.1% from 2025…

The growth of the overall pet oral care market is mainly attributed to the fundamental shift in pet ownership attitudes, where companion animals are increasingly viewed as family members deserving comprehensive healthcare, including preventive dental care to ensure long-term health and quality of life. The growth of the overall pet oral care market is mainly attributed to the fundamental shift in pet ownership attitudes, where companion animals are increasingly viewed as family members...
PR Newswire
24/06/2025

Pulmonary Drug Delivery System Market Size to Worth USD 73.14 Billion by 2031 |…

The report runs an in-depth analysis of market trends, key players, and future opportunities. In general, the pulmonary drug delivery system market comprises a vast array of products and services that are expected to register strength during the forecast period. The report runs an in-depth analysis of market trends, key players, and future opportunities. In general, the pulmonary drug delivery system market comprises a vast array of products and services that are expected to register strength...
PR Newswire
24/06/2025

Exclusive Outlook: HLA Typing Market Poised for 6.7% CAGR Growth Through 2030…

For More Information and To Stay Updated on The Latest Developments in The Global HLA Typing Market, Download FREE Sample Pages: https://www.theresearchinsights.com/request_sample?id=9536 For More Information and To Stay Updated on The Latest Developments in The Global HLA Typing Market, Download FREE Sample Pages: https://www.theresearchinsights.com/request_sample?id=9536 Market Overview and Growth Trajectory: HLA Typing Market Growth: According to an exhaustive...
PR Newswire
24/06/2025

Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing…

Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today its entry into the U.S. market and the launch of U.S.-based manufacturing through a strategic agreement with DolCas Biotech LLC (“DolCas”), a New...
Nasdaq GlobeNewswire
24/06/2025

Mangiferin Market to Surge from USD 225 Million to USD 384.5 Million by 2032 -…

This market growth is driven by the growing application of mangiferin in the cosmetics industry, increasing health and wellness trends, rising demand for natural ingredients, and growing incorporation of mangiferin in functional foods and dietary supplements. This market growth is driven by the growing application of mangiferin in the cosmetics industry, increasing health and wellness trends, rising demand for natural ingredients, and growing incorporation of mangiferin in functional foods…
PR Newswire
24/06/2025
Altri  Comunicati